COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with COPD:
- People with COPD between the ages of 18 and 77, with a mild to moderate-severe disease stage (GOLD Stage 1, 2, or 3), who are already having a bronchoscopy (a camera procedure into the airways) for a medical reason
- People with COPD between the ages of 18 and 77, with a mild to moderate-severe disease stage (GOLD Stage 1, 2, or 3), who would only be donating blood for the study
- People with COPD between the ages of 18 and 69, with a mild to moderate disease stage (GOLD Stage 1 or 2), who would be having a bronchoscopy purely for research purposes
- COPD must have been confirmed by a chest X-ray or a detailed CT scan of the chest within the past 12 months
- People who are able to give informed consent to participate
For healthy volunteers:
- Any healthy person between the ages of 18 and 77
- People who are able to give informed consent to participate
Who may not be able to join:
For people with COPD:
- People who have an active cancer, a weakened immune system, diabetes, chronic kidney disease, or liver failure
- People with a history of anaemia (low red blood cell levels)
- People who have donated more than 250 ml of blood for any reason in the past 6 months
- People who are pregnant or breastfeeding
- People currently taking part in another clinical trial, unless that trial is directly related to this study
- People who have had a fever or signs of an active infection (such as a respiratory, gut, or skin infection) in the past 2 weeks
- People who have received a vaccine in the past 2 weeks
- People who are unable to communicate in English or cannot clearly express willingness to take part
- For those having a bronchoscopy: people with an active lung infection, lung cancer, significant scarring of the lung tissue, or any additional lung condition beyond COPD that would make the procedure unsafe (confirm with trial site)
For healthy volunteers:
- People who have an active cancer, a weakened immune system, diabetes, chronic kidney disease, or liver failure
- People found to have anaemia on a blood test taken at the screening visit
- People who have donated more than 250 ml of blood for any reason in the past 6 months
- People who are pregnant or breastfeeding
- People currently taking part in any other clinical trial
- People who have had a fever or signs of an active infection (such as a respiratory, gut, or skin infection) in the past 2 weeks
- People who have received a vaccine in the past 2 weeks
- People with any chronic or acute (sudden) breathing or lung condition
- People with any ongoing medical condition or who regularly take prescription medication, except for the oral contraceptive pill
- People who are unable to communicate in English or cannot clearly express willingness to take part
- For those having a bronchoscopy: people with any active lung condition including lung infection or asthma, any significant abnormality on a chest X-ray that would make the procedure unsafe, or a lung function reading below 65% of what would be expected for their age and size (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David H Dockrell, MD, University of Edinburgh
Phone: +441312426213
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identification of immunometabolic responses in immune cells required for microbicidal activity.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.